Tukysa (tucatinib) — United Healthcare

Initial criteria

• Diagnosis of gallbladder cancer OR intrahepatic cholangiocarcinoma OR extrahepatic cholangiocarcinoma
• Disease is human epidermal growth factor receptor 2 (HER2)-positive
• Disease is unresectable OR resected gross residual (R2) OR metastatic
• Patient has received at least one prior systemic therapy
• Used in combination with trastuzumab (e.g., Kanjinti, Ogivri, Trazimera)

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Tukysa therapy

Approval duration

12 months